Investigations of Sorafenib for HCC Patients Who Have Residue Disease After Resection With Curative Intent

Trial Profile

Investigations of Sorafenib for HCC Patients Who Have Residue Disease After Resection With Curative Intent

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Acronyms SECURE
  • Sponsors Bayer
  • Most Recent Events

    • 22 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 05 Sep 2017 Planned End Date changed from 22 Aug 2017 to 8 Sep 2017.
    • 15 Aug 2017 Planned End Date changed from 31 Jul 2017 to 22 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top